Immunotherapy / PD-L1 inhibitorPhase 3 trialInvestigational
Atezolizumab
How it works
Blocks the PD-L1 protein on cancer cells, preventing them from evading immune detection.
Cancer types
Efficacy
Clinical trials demonstrate that atezolizumab can achieve response rates of around 10% in patients with metastatic colorectal cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Study Compares Lung Cancer Treatments | Lung Cancer | phase-3 | Median IRF-assessed PFS in PD-L1+ patients was 19.4 months with tiragolumab plus atezolizumab versus 16.6 months with durvalumab. | Source → |
| Melanoma Trial Examines Combination Therapy | Melanoma | phase-2 | — | Source → |
| Small Cell Lung Cancer Trial Investigates New Combination Therapy | Lung Cancer | phase-1 | — | Source → |
| Testing a Combination Treatment for Advanced Solid Tumors | Breast Cancer | phase-2 | — | Source → |
| Japanese Researchers Reconstruct Cancer Survival Outcomes from Electronic Medical Records | Lung Cancer | observational | The median progression-free survival was 3.5 months (95% CI 2.3-8.9), comparable to the 4.2 months (95% CI 2.8-4.4) reported in the OAK trial's Japanese subgroup. | Source → |
| Testing New Treatment for Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Genetically Engineered NK Cells Tested for Non-Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Guadecitabine and Atezolizumab for Advanced Blood Cancers | Leukemia | phase-1 | — | Source → |
| Evaluating Atezolizumab in Routine Lung Cancer and Liver Cancer Treatment | Lung Cancer | preclinical | — | Source → |
| Testing Focused Ultrasound to Open Blood-Brain Barrier for Lung Cancer Brain Metastases | Lung Cancer | phase-3 | — | Source → |
| Testing Combination Therapy for Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing Lurbinectedin with Atezolizumab for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing a New Treatment for Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Small Cell Lung Cancer Treatment Trial Investigates Radiotherapy and Immunotherapy Combination | Lung Cancer | phase-2 | — | Source → |
| Testing Atezolizumab and Tivozanib in Various Cancers | Breast Cancer | phase-1 | — | Source → |
| Testing Quaratusugene Ozeplasmid and Atezolizumab in Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Olaparib and Atezolizumab in BRCA Mutant Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Exploring New Treatment Combinations for Advanced Gastrointestinal Cancers | Pancreatic Cancer | phase-1 | — | Source → |
| Testing Cabozantinib and Atezolizumab for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Atezolizumab Treatment for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Testing Atezolizumab and Sacituzumab Govitecan to Prevent Triple Negative Breast Cancer Recurrence | Breast Cancer | phase-2 | — | Source → |
| Testing Atezolizumab and Capecitabine for Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Researchers Identify Potential Blood-Based Biomarkers for Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Rectal Cancer Treatment Trial Investigates Atezolizumab and Tiragolumab | Colorectal Cancer | phase-2 | — | Source → |
| Testing Natural Killer Cells and Atezolizumab for Acute Myelogenous Leukemia | Leukemia | phase-1 | — | Source → |
| New Way to Give Cancer Treatment May Be Easier for Patients | Lung Cancer | phase-1/2 | A fixed 1,875-mg SC dose every 3 weeks provides bioavailability and steady-state exposure non-inferior to IV. | Source → |
| Study of Atezolizumab, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer with Brain Metastases | Breast Cancer | phase-2 | — | Source → |
| Comparing Two Cancer Treatments in Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 9.93 months for pembrolizumab and 5.33 months for atezolizumab. | Source → |
| New Treatment Combination Shows Promise for Colon Cancer Patients | Colorectal Cancer | phase-3 | The 3-year disease-free survival was 86.3% in the atezolizumab-mFOLFOX6 group, as compared with 76.2% in the mFOLFOX6 group. | Source → |
| Tracking Cancer Evolution with Liquid Biopsy | Lung Cancer | lab-study | — | Source → |
| Testing a New Treatment for Extensive Stage Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Atezolizumab with Radiation for Early Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Radiation Therapy Followed by Atezolizumab in Non-small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Pegylated Liposomal Doxorubicin and Immunotherapy in Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Atezolizumab and Bevacizumab in Rare Solid Tumors | Lung Cancer | phase-2 | — | Source → |
| Testing Temozolomide and Atezolizumab for Metastatic or Recurrent Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Atezolizumab Dosing Study for Various Cancers | Lung Cancer | phase-1 | — | Source → |
| Atezolizumab for Metastatic Colon Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Testing Atezolizumab in Early-Stage Cutaneous Melanoma | Melanoma | phase-1 | — | Source → |
| Cost of Lung Cancer Treatments Compared | Lung Cancer | observational | — | Source → |
| Rare Side Effects from Cancer Treatment | Lung Cancer | observational | — | Source → |
| Real-world effectiveness of adjuvant atezolizumab in lung cancer patients | Lung Cancer | observational | The 2-year disease-free survival rate was 63.8%. | Source → |
| Testing Atezolizumab with Chemoradiation for Limited Stage Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| PD-L1 Assays May Predict Benefit of Cancer Treatment | Lung Cancer | review | — | Source → |
| New Cancer Treatment Shows Promise in Lab Experiments | Melanoma | lab-study | — | Source → |
| Rare Skin Reaction Linked to Cancer Treatment | Lung Cancer | observational | — | Source → |
| Atezolizumab plus chemotherapy effective in Japanese patients with advanced lung cancer | Lung Cancer | observational | Twelve-month OS rates were 62.9% (atezo + CnP), 72.1% (atezo + PP), and 68.3% (atezo + bev + CP). | Source → |
| Combining Atezolizumab with Bevacizumab and Chemotherapy for Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | The hazard ratio for overall survival was 0.83 (95% CI, 0.68 to 1.01; p = .06; median 14.2 months with atezolizumab and 13.0 months with placebo) | Source → |
| Atezolizumab Monotherapy Window in Triple-Negative Breast Cancer | Breast Cancer | phase-2 | pCR rates in study arms A and B were similar (65.7% and 69.0%, respectively). | Source → |
| Cost-effectiveness of Atezolizumab for Lung Cancer Patients | Lung Cancer | phase-3 | Adding atezolizumab to chemotherapy increased QALYs by 0.721 at an incremental cost of NT$2,111,359. | Source → |
| Combining Two Treatments May Help Fight Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Atezolizumab Compared to Docetaxel in Lung Cancer Treatment | Lung Cancer | meta-analysis | Atezolizumab had better efficacy than docetaxel for overall survival (HR: 0.77, 95% CI: 0.73 to 0.81). | Source → |
| Atezolizumab treatment may worsen eye problems in some lung cancer patients | Lung Cancer | observational | — | Source → |
| New Cancer Treatment Combination Shows Promise for Melanoma Patients | Melanoma | phase-2 | 12-month EFS was 72.0% (95%CI 57.9-89.5%), 12-month RFS was 73.3% (95%CI 56.9-94.5%), and 12-month DMFS 86.0% (95%CI 72.2-100%). | Source → |
| New Treatment Option for Advanced Lung Cancer Patients | Lung Cancer | phase-3 | Atezolizumab improved OS compared to monochemotherapy. | Source → |
| Atezolizumab May Increase Risk of Severe Blood Infections in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| New Treatment Combination Shows Promise for Rare Cancer | Leukemia | phase-2 | — | Source → |
| New Lung Cancer Treatment Shows Promise in Early Study | Lung Cancer | phase-3 | The median overall survival was 10.7 months, and the median progression-free survival was 5.5 months. | Source → |
| Elderly Lung Cancer Patients Treated with Atezolizumab | Lung Cancer | phase-2 | — | Source → |
| New Options for Lung Cancer Treatment After Surgery | Lung Cancer | phase-3 | Improved disease-free survival and, in case of PD-L1 at least 50%, also improved overall survival for atezolizumab compared to best supportive care. | Source → |
| Switching to Atezolizumab After 3 Months May Not Help Advanced Melanoma Patients | Melanoma | phase-2 | Median progression-free survival was 13.9 months in patients who continued vemurafenib plus cobimetinib, compared to 5.9 months in those who switched to atezolizumab. | Source → |
| Combination Therapy Shows Limited Effectiveness in Pancreatic and Gastric Cancers | Pancreatic Cancer | phase-1/2 | In MORPHEUS-PDAC, ORRs with atezolizumab plus PEGPH20 were 6.1% vs. 2.4% with chemotherapy. | Source → |
| Atezolizumab and Nab-Paclitaxel Combination in Advanced Breast Cancer | Breast Cancer | observational | Median progression-free survival was 3.0 months (95% CI [2.5; 3.5]) and median overall survival was 8.94 months (95% CI [4.35; 13.53]). | Source → |
| Atezolizumab May Help Some Patients with Lung Cancer and Interstitial Pneumonia | Lung Cancer | phase-2 | The 1-year survival rate was 53.3% (95% CI, 25.9-74.6). | Source → |
| Atezolizumab Improves Survival in Lung Cancer Patients | Lung Cancer | preclinical | Median overall survival was 12.5 months with atezolizumab versus 8.4 months with placebo. | Source → |
| Atezolizumab's Cost-Effectiveness in Early-Stage Lung Cancer | Lung Cancer | phase-3 | Atezolizumab produced an additional 0.45 quality-adjusted life-years (QALYs) in the PD-L1 TC ≥ 1% stage II - IIIA group. | Source → |
| Atezolizumab Helps Some Lung Cancer Patients After Surgery | Lung Cancer | phase-3 | Use of this drug was associated with a 34% reduction in the risk of disease progression compared with best supportive care among patients whose tumors expressed PD-L1. | Source → |
| Re-administering Cancer Treatment after Serious Side Effect | Lung Cancer | observational | — | Source → |
| Atezolizumab Plus Nab-Paclitaxel Therapy for Advanced Breast Cancer: Cost-Effectiveness in Japan | Breast Cancer | phase-3 | The QALYs for AnP treatment were longer than for nP treatment (1.12 vs 0.82 QALYs), but the total cost of AnP treatment was more expensive than that of nP treatment (¥11,070,143 vs ¥2,056,164). | Source → |
| Researchers Report Reproducible Cancer Effect in Lung Cancer Patient | Lung Cancer | observational | — | Source → |
| Atezolizumab May Help Lung Cancer Patients with Certain Genetic Mutations | Lung Cancer | phase-3 | Median overall survival was 7.3 months in the atezolizumab group versus 5.8 months in the docetaxel group. | Source → |
| Woman with lung cancer responds well to new treatment | Lung Cancer | observational | — | Source → |
| Lab Test May Help Predict Cancer Treatment Success | Lung Cancer | preclinical | Decrease in serum CRP as early as six weeks post treatment predicted improved PFS and OS. | Source → |
| Atezolizumab's Effectiveness in Cancer Treatment and the Role of PD-L1 Expression | Lung Cancer | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.